Protein kinase C (PKC) regulates activation of the Raf-1 signaling cascade by growth factors, but the mechanism by which this occurs has not been elucidated. Here we report that one mechanism involves dissociation of Raf Kinase Inhibitory Protein (RKIP) from Raf-1.
INTRODUCTION
The MAP kinase cascade, an evolutionarily conserved signaling module, stimulates numerous biological processes including growth and differentiation. The known elements of the pathway include a MAP kinase kinase kinase that phosphorylates and activates a MAP kinase kinase, which in turn phosphorylates the TXY activation domain of MAP kinase (reviewed in (1) ). The first characterized subfamily of MAP kinases, termed extracellular signal regulated kinases (ERKs), is activated by growth factors and other stimuli via a cascade involving Ras, Raf-1 kinase, and MEK/ERK kinase (MEK). Activation of MAP kinase is under exquisite regulatory control, particularly at the level of Raf-1 activation. The N-terminal regulatory domain of Raf-1 interacts with Ras leading to dephosphorylation at negative regulatory sites, conformational changes to expose the kinase domain, and subsequent phosphorylation at activating sites such as serine 338 (S338) and tyrosine 341 (Y341) (reviewed in (2)). A variety of studies have shown that protein kinase C (PKC) isozymes are also capable of activating Raf-1 (3) (4) (5) and/or the downstream MEK (6) , but the mechanism has not been elucidated.
The PKC family of serine/threonine kinases are key mediators of several physiological processes including growth, death, differentiation and transformation (reviewed in (7)). There are three major classes of PKCs that are distinguished by their physiological activators. The classical PKCs (a, bI, bII and g) require both Ca 2+ and diacylglycerol (DAG) for activation including direct phosphorylation of either MEK (12) or Raf-1. While the phosphorylation of MEK by PKCs is controversial (6) , Raf-1 is phosphorylated by PKCs at multiple sites. For example, PKCa phosphorylates Raf-1 at serine 499 (13) but mutation of this residue did not impede activation of Raf-1 by the physiological stimulators Ras and Lck. Similarly, both v-Src and phorbol esters were able to activate Raf-1 even though the PKC phosphorylation sites at serine 497 and serine 499 were mutated to alanine (14) . Thus, while some PKC phosphorylation sites on Raf-1 have been identified, these sites do not appear to be required for activation of Raf-
1.
Recent studies from our laboratory suggest that ERK activation is mediated by specific PKC isoforms in response to different growth factors. In both the conditionally-immortalized hippocampal cell line H19-7 (15) and primary E16 rat hippocampal cells, two different PKC isoforms, PKCz and PKCd, mediate ERK activation by epidermal growth factor (EGF) and fibroblast growth factor (FGF), respectively (10, 11) . Both PKCs are required for activation of ERKs at a step upstream of MEK and either downstream or at the level of Raf-1. While these studies suggested that PKCz activates Raf-1 in response to EGF, phosphorylation of neither Raf-1 nor MEK appeared to be responsible ( (3, 6, 16) and data not shown). Furthermore, phosphatase inhibitors such as okadaic acid did not alleviate the requirement for PKC (data not shown). We therefore considered the possibility that Raf-1 regulatory proteins might be potential targets of PKC.
RKIP, the Raf-1 kinase inhibitor protein, was recently identified by yeast two-hybrid cloning utilizing the kinase domain of Raf-1 as bait (17) . RKIP was found to be a member of the phosphatidylethanolamine-binding protein (PEBP) family, a ubiquitously expressed protein with homologues in A. thaliana, S. cerevisiae, C. elegans, and D. melanogaster that display high degrees of interspecies sequence similarity (18) . There are at least three RKIP-like PEBPs in rat, two in mice, and one in human (19) . Also, amino acids 2-12 of PEBP are identical to the hippocampal cholinergic neurostimulatory peptide (HCNP) that stimulates acetylcholine synthesis in rat septal nuclei (20) . PEBPs are distinct from other known proteins, and their function has remained largely enigmatic. In addition to binding phospholipids, PEBPs bind nucleotides and opioids and were recently shown to inhibit thrombin (21) . A role for PEBP in signaling was demonstrated when it was shown that RKIP binds to Raf-1. RKIP itself is neither a kinase nor a substrate for Raf-1 or MEK (17) , but has been reported to be a specific inhibitor of MEK binding to Raf-1 (22) , suppressing both Raf-1-induced transformation and AP-1-dependent transcription.
In the present study we demonstrate that one mechanism by which PKCs activate Raf-1 signaling to ERK involves the loss of inhibition by RKIP. Although both phorbol esters and
PKCs have been well established as activators of MAP kinases, the targets for PKCs in this pathway are surprisingly unknown. Since phorbol esters are tumor promoters and several components of the MAP kinase pathway are mutated in human cancers, the mechanism of PKCmediated Raf/MAP kinase activation is of paramount importance. These results provide an explanation of how PKCs can physiologically regulate Raf-1 signaling.
EXPERIMENTAL PROCEDURES

Plasmid construction
All constructs were made by the polymerase chain reaction (PCR) using pCMV-HA-RKIP as template (a gift from K. Yeung, Brown University). The forward (F) and reverse (R) primers were as follows: (F) 5' atg gcc gcc gac atc agc cag tgg 3'; (R) 5' ctt ccc agc cag ctg atc gtg cag 3'. For the pCR-HA-and FLAG-RKIP constructs the forward primers were as follows: (F-HA)
5' ggc tcc atc atg tac cca tat gac gtt cca gac tac gct gcc gcc gac atc agc cag tgg 3'; (F-FLAG) 5' ggc tcc atc atg gac tac aag gac gac gac gac aag gcc gcc gac atc agc cag tgg 3'. The reverse 6 digestion and ligated into EcoRI-digested pGEX-2T (Amersham-Pharmacia). Site-directed mutagenesis of S153 to valine was done utilizing pGEX-RKIP as template and the U.S.E. kit (Amersham-Pharmacia). The following mutagenic primer was used: 5' gta ctt ctt tcg aaa gac ctc cac ctt gaa ctt 3'. This primer binds to the negative strand of pGEX-RKIP and introduces a silent mutation resulting in the creation of a unique BstBI site and conversion of S153 to valine. The NarI/NheI selection primer was from Amersham/Pharmacia. The mutation was confirmed by sequencing in both directions. The S153 to glutamic acid (S153E) mutagenesis was done utilizing pGEX-RKIP as template and the QuickChange kit (Stratagene). The mutagenic primer was as follows: 5' ggc aag ttc aag gtg gag gag ttt cga aag aag 3'. This primer introduces a silent mutation, resulting in the creation of a unique BstBI site and conversion of S153 to glutamic acid. The mutation was confirmed by sequencing in both directions. The HA-and FLAGtagged RKIP(S153V) and (S153E) plasmids were constructed by PCR utilizing the appropriate pGEX-RKIP plasmid as template. The F-HA and F-FLAG forward primers were used along with the R-stop reverse primer and ligated into the pCR3.1 vector to make pCR-HA-and FLAG-RKIP(S153V) and (S153E).
In vitro PKC kinase assays
1 mg of GST-RKIP or GST-RKIP(S153V) was combined with 200 ng baculovirusderived PKC (Panvera) in 50 ml of kinase buffer. For PKCa, bI, bII and g the buffer used was 20 mM HEPES, pH 7.4, 100 mM CaCl 2 , 10 mM MgCl 2 , 100 mg/ml L-a-phosphatidylserine and 20 mg/ml diacylglycerol. The buffer used for novel PKCs d, e and h was 25 mM Tris, pH 7.5, 5
mM MgCl 2 , 0.5 mM EGTA, 200 mg/ml L-a-phosphatidylserine and 20 mg/ml diacylglycerol.
The buffer for PKCz was 25 mM Tris, pH 7.5, 5 mM MgCl 2 , 0.5 mM EGTA, 1 mM DTT, 100 mg/ml L-a-phosphatidylserine. Samples were aliquoted from premixed cocktails to ensure that the amounts of CBP-CR3 or PKCz were the same in different tubes. The reactions were started by the addition of 5 mCi 32 P-g-ATP, carried out at 30°C for 30 minutes, and then stopped by the by guest on September 1, 2017
http://www.jbc.org/ Downloaded from addition of 6X sample buffer and heating at 100°C for 3 minutes. The samples were loaded onto a 10% acrylamide gel, transferred to nitrocellulose, and exposed to film.
Cell culture
The immortalized H19-7 cells were generated from embryonic rat hippocampal cells and grown as previously described (15) . H19-7 cells were maintained in 10% fetal bovine serum (FBS), 50u/ml penicillin-50 mg/ml streptomycin, and 200mg/ml G418 at 33°C. Cells were serum starved at 39°C in N2 medium or DMEM overnight prior to treatment. COS-7 cells were grown in DMEM with 10% FBS and 50u/ml penicillin-50 mg/ml streptomycin.
In vitro HA-ERK2 activation assays
H19-7 cells were transfected with 10 mg of DNA per 10 cm plate using TransIT-LTI (Panvera). DNA in all transfections was added to equal amounts by addition of empty vector where necessary. 24 hours following transfection, cells were starved overnight followed by treatment with 800 nM tetradecanoyl phorbol acetate (TPA) or 100 ng/ml EGF. HA-ERK2
kinase assays were performed in vitro as described previously with either GST-Elk-1 or MBP as substrates (11) . The amount of HA-ERK2 in each sample was determined by immunoblot analysis with an anti-HA monoclonal antibody (3F10, Roche). Relative kinase activity was measured with a phosphoimager and normalized to the amount of HA-ERK2 in each sample.
For down-regulation of endogenous RKIP, H19-7 cells were transfected with empty vector, HA-ERK2, or HA-ERK2 plus the RKIP antisense construct AS-C143 and pHACT (17) . 24 hours later, cells were starved overnight and activation of HA-ERK2 was assayed as above. In some experiments, ERK activation was determined by immunoblotting with antiphosphoMAPK antibodies. Samples were quantified by digital analysis (Alpha Innotech).
In vitro GST binding assays
In vitro binding assays were carried out as described (23) polyacrylamide gel, transferred to nitrocellulose, and immunoblotted with anti-Raf-1 antibodies.
Raf and RKIP co-immunoprecipitations
Co-immunoprecipitation of Raf and RKIP were carried out in a modification of a previously described procedure (17) . To observe association, immunoprecipitations were done with similarly mild conditions of sonication in phosphate-buffered saline without detergent. 7 mg of myc-Raf-1 and 3 mg of HA-RKIP or HA-RKIP(S153V) were transfected into COS-7 cells. 24
hours later, cells were starved overnight and subsequently treated as indicated in the figures.
Cells were lysed by sonication in cold PBS plus protease inhibitors and cleared by centrifugation. To IP myc-Raf-1, 1 mg of anti-myc monoclonal antibody (9E10, Upstate Biotechnology) was added to 250 mg of cell lysate proteins and rotated at 4°C followed by addition of 25 ml of Protein G-sepharose (1:1 slurry). The complex was washed 3 times with cold PBS and boiled in 3X PAGE sample buffer. The proteins were separated in 12.5% polyacrylamide gels, transferred to nitrocellulose, and immunoblotted with anti-HA antibodies
RESULTS
Endogenous RKIP is a physiological inhibitor of EGF-and TPA-induced ERK activation.
In order to determine if RKIP is able to inhibit ERK activation by EGF or tetradecanoyl phorbol acetate (TPA) in H19-7 cells, exogenous RKIP was introduced into cells. Plasmids expressing HA-ERK2 and FLAG-RKIP were co-transfected into H19-7 cells, and activation of HA-ERK upon cell stimulation was measured by an in vitro kinase assay using Elk-1 as a substrate. As shown in Fig. 1A , overexpression of RKIP is able to block HA-ERK2 activation by EGF and TPA. These results indicate that RKIP is capable of inhibiting the activation of ERK by these stimuli. To determine whether endogenous RKIP normally regulates ERK activity, an antisense RKIP construct, pAS-C143 that was previously shown to suppress endogenous RKIP (17), was co-transfected along with HA-ERK2 into H19-7 cells, and HA-ERK2 activation was assayed before and after EGF or TPA stimulation ( 
PKCs are RKIP kinases.
Having established that RKIP regulates the EGF and TPA-stimulation of ERK (see Fig.   1A ) and previously demonstrated a requirement for PKCz in EGF-stimulated ERK activation, we investigated whether RKIP and PKCs could directly interact. An analysis of the RKIP protein sequence for PKC consensus phosphorylation sites (24) identified serine 153 (S153) of the rat RKIP sequence as a potential target. This site was mutated to a non-phosphorylatable valine residue (S153V), and the mutant RKIP was cloned into a bacterial expression vector to produce recombinant GST-RKIP(S153V). Purified GST-RKIP and GST-RKIP(S153V) were then used as substrates for PKC in in vitro kinase assays. As shown in Fig. 1C , RKIP is a substrate for PKCa, bI, bII, g and z, and substitution of S153 prevents most of this phosphorylation. Overexposure of the blot reveals some additional phosphorylation by PKCs a and g, but the amount is low compared to the phosphorylation of S153. These data demonstrate that S153 is the major site of RKIP phosphorylation by PKC. Interestingly, the novel PKCs, including, PKCd, e and h, are not RKIP kinases in vitro, suggesting that RKIP phosphorylation is not a feature of all PKC isozymes.
Since PKCz is able to phosphorylate RKIP, we determined whether PKCz and RKIP could associate in vitro and in vivo. We focused on the PKCz isoform based on our previous work indicating that PKCz mediates Raf-1 activation by EGF in H19-7 cells (11); however, since classical PKCs can phosphorylate RKIP in vitro, we expect that they would also physically associate and mediate the action of TPA as well as specific growth factors dependent upon the particular cell type. As shown in Fig. 1D , recombinant PKCz binds to GST-RKIP but not GST.
These results indicate that RKIP and PKCz are capable of specifically interacting. However, no stable association was detected in vivo (data not shown), consistent with an enzyme/substrate interaction.
Phosphorylation of RKIP by PKC causes release of RKIP from Raf-1 and increased ERK activation.
Since PKCz potentiates Raf activity (11), we determined whether direct phosphorylation of RKIP by PKCz could result in the release of RKIP from Raf-1. To test this possibility in vitro, GST, GST-RKIP, or GST-RKIP(S153V) were pre-bound to Glutathione-Sepharose beads and incubated with a bacterially-expressed Raf-1 kinase domain (CBP-CR3) (25), the region of Raf that binds to RKIP. The Raf-1 kinase domain bound to both wild-type RKIP and RKIP (S153V) ( Fig. 2A) . Addition of purified PKCz and ATP led to the release of the Raf-1 kinase domain from GST-RKIP but not from GST-RKIP (S153V), demonstrating that phosphorylation of S153 on RKIP by PKCz causes dissociation of the Raf-1 kinase domain and RKIP.
To test the effect of PKC on the interaction of RKIP with full-length Raf-1 in cells, mycRaf-1 was co-transfected into COS-7 cells with HA-RKIP or HA-RKIP(S153V), and the association of the two molecules was determined before and after TPA stimulation. In agreement with previously published results (22), we observed that transfected myc-Raf-1 and HA-RKIP could be co-immunoprecipitated from starved COS-7 cells, and that activation of PKC by TPA alone induced the release of HA-RKIP from myc-Raf-1 (Fig. 2B) . Analysis of the cell lysates by immunoblotting indicated that both TPA-treated and untreated cells contain comparable levels of HA-RKIP (data not shown). Treatment of H19-7 cells with physiological PKC activators such as EGF also induced dissociation of endogenous RKIP from endogenous cRaf-1 by 59%, as shown using an HRP-tagged anti-RKIP antibody for immunoblotting to eliminate background from light chain antibody (Fig. 2C) . If the mechanism for RKIP dissociation from Raf-1 involves phosphorylation of RKIP by PKC, then the mutant RKIP(S153V) should remain bound to Raf-1 independent of PKC activation. Consistent with this prediction, HA-RKIP(S153V) co-immunoprecipitated with myc-Raf-1 in both resting and TPA-treated COS-7 cells (Fig. 2B) . Similar results were obtained when GST-Raf rather than myc-Raf was co-expressed with RKIP, and the complexes were isolated using glutathione beads (data not shown). These results indicate that PKC can regulate RKIP binding to Raf-1 kinase in vivo by phosphorylating RKIP at residue S153.
Endogenous RKIP is phosphorylated at S153 in vivo.
Since the above phosphorylation studies used exogenous RKIP, we determined whether endogenous cellular RKIP is similarly phosphorylated at S153 in response to PKC activation.
Therefore, we generated antibodies against phosphorylated S153 RKIP (a-pS153-RKIP) by immunizing rabbits with a 12 amino acid peptide containing residues 146-157 of the rat RKIP sequence with a phosphoserine at position 153, and purifying the antibody via peptide affinity chromatography. To test the specificity of the antibody, GST-RKIP and GST-RKIP(S153V)
were initially incubated with recombinant PKC and ATP to phosphorylate RKIP. The products of this reaction were then resolved by SDS PAGE along with GST, unphosphorylated GST-RKIP, GST-RKIP(S153V) and GST-RKIP(S153E), a mutant of GST-RKIP with glutamic acid substituted at residue 153 to mimic phosphorylation at this site. Immunoblot analysis with the purified a-pS153-RKIP antibody strongly detected a single 48 kDa band corresponding to GST-RKIP that was phosphorylated by PKC (Fig. 3A) . In contrast, the antibody did not recognize unphosphorylated GST-RKIP, GST, GST-RKIP (S153V) or GST-RKIP(S153E). These data demonstrate that the purified antibody specifically detects RKIP phosphorylated at S153.
Since phorbol esters are the most robust and specific activators of PKCs, we initially demonstrates that RKIP is phosphorylated on S153 in vivo in a PKC-dependent manner.
To determine if the physiological activator EGF can induce phosphorylation of RKIP by PKC, two approaches were utilized. In one set of experiments, H19-7 cells were transfected with FLAG-tagged RKIP or (S153V)RKIP. Following treatment of cells with 100 ng/ml nM EGF for 2-15 minutes, FLAG-RKIP was isolated from cell lysates using an anti-FLAG affinity column and eluted with FLAG peptide. After separation by SDS PAGE, the induction of phosphorylated RKIP was determined by immunoblotting with the a-pS153-RKIP antibody.
As shown in Fig. 3C , EGF stimulated phosphorylation of RKIP, and the peak of phosphorylation occurred at 2 minutes. This time course corresponds to those of Raf and ERK activation which also peak at 2 minutes in response to EGF in H19-7 cells (data not shown). In an alternative approach involving endogenous RKIP, H19-7 cells were incubated with 100 ng/ml EGF for 2 minutes. Phospho(S153)RKIP was measured by immunoblotting cell lysates with a-pS153-RKIP antibody and then normalizing the results to tubulin. As shown in Fig. 3D , EGF treatment caused an increase in phosphoRKIP of approximately 2-fold in H19-7 cells. These results indicate that RKIP is phosphorylated at S153 in response to cell stimulation by the physiological activator EGF.
Glutamate does not act as a phosphomimetic when substituted at residue S153.
Since the crystal structure of bovine PEBP (RKIP) has been solved to a resolution of 1.84
Å (26), we used molecular modeling to explore the relationship of S153 to the functional domains of RKIP. Purified RKIP crystallizes as a dimer (26) and the monomer is shown in Fig.   4A , with the evolutionarily conserved phosphatidylethanolamine binding (PEB) domain (residues 64-86) colored in green and the PKC phosphorylation site (S153) in blue. The PEB domain consists of hydrophobic residues that form a b-sheet and mediate the high affinity binding of membrane phosphatidylethanolamine (26). Interestingly, S153 lies on the surface of RKIP in a loop domain that has more variability than other conserved regions of RKIP. To address the structural consequences of phosphorylation, we modeled the RKIP structure with a phosphorylated S153 residue (Fig. 4A) . The added phosphate group strikingly extends into the potential Raf-1 binding pocket, supporting our data that phosphorylation at this site mediates the release of Raf-1 from RKIP. Substitution of a glutamic residue at this site (S153E) results in a slightly larger group than the original serine residue, but one that is not as bulky as the phosphoserine (Fig. 4A ).
Since glutamic acid residues can mimic phosphoserine residues under some circumstances, we determined whether a mutant RKIP with glutamic acid substituted at residue 153 (S153E) would still bind to Raf-1. In fact, GST-RKIP(S153E) bound to the Raf-1 kinase domain (CBP-CR3) at least as well as GST-RKIP or GST-RKIP(S153V) in vitro (Fig. 4B) , suggesting that steric hindrance by the phosphate group rather than the negative charge is responsible for the inability of phosphoRKIP to bind. To determine whether an RKIP mutant with glutamic acid replacing S153 might also promote binding to full-length Raf-1 in vivo, we transfected COS-7 cells with a vector expressing HA-RKIP, HA-RKIP(S153E), or HA-RKIP(S153V). The use of highly transfectable COS-7 cells enabled us to titrate the amount of transfected RKIP cDNA to maximize inhibition. Consistent with the in vitro binding results, HA-RKIP(S153E) was as effective in blocking EGF-induced ERK activation as HA-RKIP or HA-RKIP(S153V) (Fig. 4C,4D) . Similar results were observed with H19-7 cells (data not shown). Taken together, these data demonstrate that S153 is situated on the surface of RKIP and modulates RKIP binding to Raf-1.
PKC phosphorylation rescues inhibition of ERK by RKIP but not by the S153V RKIP mutant.
If PKC phosphorylation of S153 causes the physical release of RKIP from Raf-1, then enhanced expression and activation of PKC should be sufficient to overcome the RKIP-mediated inhibition of ERK in cells. However, if the site of PKC phosphorylation is removed, then no significant rescue by PKC should be observed. To test this hypothesis, FLAG-RKIP or FLAG-RKIP(S153V) were co-expressed with HA-ERK2 in H19-7 cells, and activation of HA-ERK2
following EGF stimulation was assayed by in vitro kinase assays. Expression of the mutant FLAG-RKIP as well as the wild-type FLAG-RKIP blocks EGF-induced HA-ERK2 activation.
Co-transfection of FLAG-PKCz is able to overcome this inhibition in cells expressing FLAG-RKIP but not mutant FLAG-RKIP(S153V), indicating that PKC can mediate activation of ERK in vivo by phosphorylation of RKIP (Fig. 5) . Similar results were obtained using COS-7 cells, and similar levels of PKCz were detected in cell lysates (data not shown). These results demonstrate that Raf-1 signaling to ERK as well as its physical association with RKIP is regulated by phosphorylation of RKIP at S153.
Model for Regulation of RKIP by PKC
The results described here can be summarized in a relatively simple model that explains how PKCz can activate the Raf-1 signaling cascade in response to EGF (Fig. 6) .
Dephosphorylation of Raf-1 at residue S259 upon association with EGF-activated Ras results in release of 14-3-3 (2). PKCz can be recruited to Raf-1 by binding to 14-3-3, and subsequently released from Raf-1 by phosphorylating 14-3-3 (27). Our results suggest that PKCz can also associate with RKIP and phosphorylate residue S153 on RKIP, causing RKIP to be released from Raf-1. However, if a S153V or S153E mutant is expressed, then RKIP inhibition would not be overridden by growth factor signaling via PKC. Since RKIP prevents MEK phosphorylation, release of RKIP from Raf-1 also enhances downstream signaling to ERKs. surprising that TPA is a more potent inducer of RKIP phosphorylation.
DISCUSSION
The fact that substitution of glutamic acid for S153 did not mimic the phosphorylated residue is not surprising in light of the crystal structure. These results are analogous to those seen with the S259 negative regulatory site of Raf-1. This residue is phosphorylated by protein RKIP is a member of a larger family of phosphatidyl ethanolamine binding proteins (PEBPs). In addition to the RKIP-like PEBPs, there is also one more distant family with orthologs in humans and mice (19) . Whether all members of the PEBP family act in a similar fashion to regulate kinases is unclear. Interestingly, the residue corresponding to RKIP S153 in PEBP2, another isoform of RKIP (GenBank Accession # AF226629) is an alanine, suggesting a different mode of regulation. While the structure and key residues of the PEB binding domain of RKIP are conserved from bacteria to mammals, the loop containing S153 is more variable, 
